|Last Price$0.67||Day Change (%)-1.98%|
|Open Price$0.68||Day Change ($)-0.01|
|Day Range0.65–0.69||52-Week Range0.41–1.70|
As of Wed 4/1/2015 2:11:00 PM | USD
GTx GTXI announced Thursday that the Data Safety Monitoring Board has given it the green light to proceed with Phase III trials for Acapodene. We're leaving our fair value estimate unchanged as we had anticipated a smooth interim review. In our opinion, Acapodene's potential exposure to generic ...
GAIN Capital Announces Monthly Metrics for February 2015
Research and Markets: Global Cancer Cachexia Therapeutics Pipeline Review 2015 - 15 Companies & 25 Drug Profiles
GTx adds a European partner.
We are raising GTx's fair value on recent positive Phase II trial results for Ostarine.